United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

19 Jun 2019
Change (% chg)

$-0.12 (-1.57%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Randall, Lorin 

Mr. Lorin Jeffry Randall is an Independent Director of Acorda Therapeutics, Inc. Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004, Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001, Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publicly-traded manufacturer of semiconductor manufacturing equipment. He currently serves on the boards of directors of Athersys, Inc. where he serves as Chairman of the Audit Committee and Chairman of the Compensation Committee, and Aurinia Pharmaceuticals Inc. where he serves as Chairman of the Audit Committee and Lead Independent Director. In addition, within the last five years, he previously served on the boards of directors of Nanosphere, Inc. and Tengion, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University. As a former Chief Financial Officer of a number of publicly-traded companies, Mr. Randall possesses financial acumen acquired through working experience, including an understanding of financial matters and the preparation and analysis of financial statements. The Board has determined that Mr. Randall qualifies as an audit committee financial expert. Also, based on his broad industry and corporate experience, Mr. Randall serves as Chair of our Nominations and Governance Committee.

Basic Compensation

Total Annual Compensation, USD 70,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 94,500
Fiscal Year Total, USD 164,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen


Richard Batycky


David Lawrence


Jane Wasman


Burkhard Blank


Lauren Sabella

As Of  30 Dec 2017